cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.8233590
title: Project BioDyn: compilation of long-term (&gt;20yrs) community timeseries data from terrestrial and freshwater realms

description: The given dataset was compiled for n=2668 communities (242 study IDs in total, see the metadata file) across terrestrial and freshwater realms (terrestrial birds: n=1259, invertebrates: n=124, plants: n=435, and mammals: n=136, freshwater fish: n=587, invertebrates: n=112, and phytoplankton: n=15). Community timeseries include species-level abundance (or biomass in 15% of cases) and a minimum of 20 years sampled. We have compiled this data and used it for the first time to analyze how community stability and its drivers (species richness, overall synchrony, and tail-dependent synchrony) would differ across realms.
description: The authors thank David Vasseur for getting the requested data from a published article with no open data. We thank the ETH Board for funding through the Blue-Green Biodiversity (BGB) Initiative 2020, the Seehausen/Eawag lab and European Research Council under the European Union's Horizon 2020 research and innovation program (grant agreement No 787638) granted to Catherine H. Graham. We would like to thank the large number of scientists and volunteers that contributed to long-term data collection, and the data providers who chose to openly publish and share their datasets for continued analysis.
DOI: 10.6084/m9.figshare.23866962.v41
title: Untitled Item

description: Regridding Global CMIP6 GCMs dataset(0.5 degree)Historical dataset: 7 CMIP6 GCMs (1850-2014, ACCESS-CM2 to GFDL-ESM4)Future dataset: 7 CMIP6 GCMs and 4 SSP scenarios (2015-2100)Composition of dataset: Average temperature, Maximum temperature, Minimum temperature, Windspeed, Relative humidity, Solar radiationIf you are using our codes and dataset, please use the following references:Song, Y.H., Chung, E.S., Shahid, S., Kim, Y.J., Kim, D.K. 2023. Development of global monthly dataset of CMIP6 climate variables for estimating evapotranspiration. Scientific Data.<br>
DOI: 10.57745/d3m60g
title: 230807_readme_v1.txt

description: Dataset description
DOI: 10.57745/qssz8d
title: 230807_Dataset_v1.tab

description: Dataset
DOI: 10.15468/ywcg4j
title: tommelen

description: This database comprises information on local environmental variables and occurrence data of macro-invertebrates and aquatic plants from 22 bomb crater ponds in nature reserve Tommelen (Hasselt, Belgium) over a period of 4 years. A subset of the ponds has been dregded over winter in 2008. A number of ponds is connected to a small ditch.
DOI: 10.6084/m9.figshare.23301449
title: Supplementary Material for: Adverse Event Profile of Azacitidine: Analysis by Route of Administration using Japanese Pharmacovigilance Database

description: Intoroduction: Azacitidine is a useful drug for myelodysplastic syndromes and acute myeloid leukemia. In clinical trials, hematologic toxicity, infection have been observed as adverse events (AEs) of this drug. However, information on the time to onset of high-risk AEs and subsequent outcomes, as well as differences in the frequency of AEs due to the route of administration is lacking. In this study, we investigated azacitidine-induced AEs comprehensively using the Japanese Adverse Event Reporting Database (JADER) published by the Pharmaceuticals and Medical Devices Agency, with disproportionate analysis of AE incidence trends, time to onset, and subsequent outcomes. In addition, we analyzed the differences in AEs by route of administration and the number of days until the occurrence of AEs and generated hypotheses. Methods: The study used JADER data reported from April 2004 to June 2022. Risk estimation was conducted using reported odds ratio (ROR). A signal was detected when the lower limit of the 95% confidence interval of the calculated ROR was ≥ 1. Results: A total of 34 signals were detected as AEs due to azacitidine. Among them, 15 were hematologic toxicities, and 10 were infections, which demonstrated a particularly high rate of death. Signals of AEs such as tumor lysis syndrome (TLS) and cardiac failure, which have been described in case reports, were also detected, and the rate of death after onset was high. In addition, more AEs generally occurred within the first month of treatment. Discussion/Conclusion: The results of this study suggest that more attention should be paid to cardiac failure, hematologic toxicity, infection, and TLS. Because in clinical trials have discontinued treatment due to serious AEs before the therapeutic effect became apparent, appropriate supportive care, dose reduction, and drug withdrawal are important for the continuation of treatment.
DOI: 10.6084/m9.figshare.23301449.v1
title: Supplementary Material for: Adverse Event Profile of Azacitidine: Analysis by Route of Administration using Japanese Pharmacovigilance Database

description: Intoroduction: Azacitidine is a useful drug for myelodysplastic syndromes and acute myeloid leukemia. In clinical trials, hematologic toxicity, infection have been observed as adverse events (AEs) of this drug. However, information on the time to onset of high-risk AEs and subsequent outcomes, as well as differences in the frequency of AEs due to the route of administration is lacking. In this study, we investigated azacitidine-induced AEs comprehensively using the Japanese Adverse Event Reporting Database (JADER) published by the Pharmaceuticals and Medical Devices Agency, with disproportionate analysis of AE incidence trends, time to onset, and subsequent outcomes. In addition, we analyzed the differences in AEs by route of administration and the number of days until the occurrence of AEs and generated hypotheses. Methods: The study used JADER data reported from April 2004 to June 2022. Risk estimation was conducted using reported odds ratio (ROR). A signal was detected when the lower limit of the 95% confidence interval of the calculated ROR was ≥ 1. Results: A total of 34 signals were detected as AEs due to azacitidine. Among them, 15 were hematologic toxicities, and 10 were infections, which demonstrated a particularly high rate of death. Signals of AEs such as tumor lysis syndrome (TLS) and cardiac failure, which have been described in case reports, were also detected, and the rate of death after onset was high. In addition, more AEs generally occurred within the first month of treatment. Discussion/Conclusion: The results of this study suggest that more attention should be paid to cardiac failure, hematologic toxicity, infection, and TLS. Because in clinical trials have discontinued treatment due to serious AEs before the therapeutic effect became apparent, appropriate supportive care, dose reduction, and drug withdrawal are important for the continuation of treatment.
DOI: 10.6084/m9.figshare.23500869
title: Supplementary Material for: Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma –clinical results show importance of hepatic reserve function

description: Background/Aim: Lack of an established methodology for post-progression systemic treatment following atezolizumab plus bevacizumab (Atez/Bev) administration is an important clinical issue. The present study aimed to elucidate the potential of lenvatinib as a second-line treatment option after Atez/Bev failure. Materials/Methods: From 2020 to 2022, 101 patients who received lenvatinib as second-line treatment were enrolled (median 72 years, males 77, Child-Pugh A 82, BCLC-A:B:C:D=1:35:61:4), while 29 treated with another molecular targeting agent (MTA) during the period as second-line treatment were enrolled as controls. The therapeutic efficacy of lenvatinib given as second-line treatment was retrospectively evaluated. Results: Median progression-free survival/median overall survival for all patients was 4.4/15.7 months and for those with Child-Pugh A was 4.7 months/not-reached. When prognosis was compared with patients who received another MTA, there was no significant difference for PFS (3.5 months, P=0.557) or OS (13.6 months, P=0.992), and also no significant differences regarding clinical background factors. mRECIST findings showed that objective response and disease control rates in patients treated with lenvatinib were 23.9% and 70.4%, respectively (CR:PR:SD:PD=3:14:33:21), while those shown by RECIST, ver. 1.1, were 15.4% and 66.2%, respectively (CR:PR:SD:PD=1:10:36:24). Adverse events (any grade ≥10%) were appetite loss (26.7%) (grade 1:2:3=2:15:10), general fatigue (21.8%) (grade 1:2:3=3:13:6), protein in urine (16.8%) (grade 1:2:3=0:4:13), and hypertension (13.9%) (grade 1:2:3=1:8:5). Conclusion: Although lenvatinib treatment might not provide a pseudo-combination immunotherapy effect following Atez/Bev failure, lenvatinib when used as second-line treatment after Atez/Bev failure might be expected to be comparable as compared to its use as first-line treatment.
DOI: 10.6084/m9.figshare.23500869.v1
title: Supplementary Material for: Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma –clinical results show importance of hepatic reserve function

description: Background/Aim: Lack of an established methodology for post-progression systemic treatment following atezolizumab plus bevacizumab (Atez/Bev) administration is an important clinical issue. The present study aimed to elucidate the potential of lenvatinib as a second-line treatment option after Atez/Bev failure. Materials/Methods: From 2020 to 2022, 101 patients who received lenvatinib as second-line treatment were enrolled (median 72 years, males 77, Child-Pugh A 82, BCLC-A:B:C:D=1:35:61:4), while 29 treated with another molecular targeting agent (MTA) during the period as second-line treatment were enrolled as controls. The therapeutic efficacy of lenvatinib given as second-line treatment was retrospectively evaluated. Results: Median progression-free survival/median overall survival for all patients was 4.4/15.7 months and for those with Child-Pugh A was 4.7 months/not-reached. When prognosis was compared with patients who received another MTA, there was no significant difference for PFS (3.5 months, P=0.557) or OS (13.6 months, P=0.992), and also no significant differences regarding clinical background factors. mRECIST findings showed that objective response and disease control rates in patients treated with lenvatinib were 23.9% and 70.4%, respectively (CR:PR:SD:PD=3:14:33:21), while those shown by RECIST, ver. 1.1, were 15.4% and 66.2%, respectively (CR:PR:SD:PD=1:10:36:24). Adverse events (any grade ≥10%) were appetite loss (26.7%) (grade 1:2:3=2:15:10), general fatigue (21.8%) (grade 1:2:3=3:13:6), protein in urine (16.8%) (grade 1:2:3=0:4:13), and hypertension (13.9%) (grade 1:2:3=1:8:5). Conclusion: Although lenvatinib treatment might not provide a pseudo-combination immunotherapy effect following Atez/Bev failure, lenvatinib when used as second-line treatment after Atez/Bev failure might be expected to be comparable as compared to its use as first-line treatment.
DOI: 10.5517/ccdc.csd.cc2dgkt8
title: CCDC 2218540: Experimental Crystal Structure Determination

description: Related Article: Letao Jin, Ziyu Song, Heng Zhang, Zhibin Zhou, Wenfang Feng|2023|Energy Adv|2|1122|doi:10.1039/D3YA00110E
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2dgkxc
title: CCDC 2218543: Experimental Crystal Structure Determination

description: Related Article: Letao Jin, Ziyu Song, Heng Zhang, Zhibin Zhou, Wenfang Feng|2023|Energy Adv|2|1122|doi:10.1039/D3YA00110E
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5281/zenodo.8120921
title: Cipher Machine Siemens Mischer 178 (Inv. 1989-626)

description: This dataset represents the computed tomography image acquisition of a historical cipher machine from the collection of the Deutsches Museum. It is composed of CT reconstructed image stacks in the DICOM (.dcm) format.<br> It can be imported in any free or propietary CT-Viewer that supports the DICOM standard to generated 2D and 3D imaging.<br> If segmentations/ROIs are availabe, they are uploaded in a seperate image stacks and are a subset of the scanned cipher machine. object details:<br> name: Siemens Mischer 178<br> Inv.-No. of the Deutsches Museum: 1989-626 file object details:<br> file format: image/dcm<br> pixel spacing unit: mm<br> X pixel spacing: 0.670<br> Y pixel spacing: 0.670<br> Z pixel spacing: 0.600<br> grid size x: 569<br> grid size y: 492<br> grid size z: 1099<br> color depth: 16Bit ownership & image acquisition:<br> project: 3D-Cipher<br> collection: Deutsches Museum<br> IP holder: Deutsches Museum<br> license: Creative Commons BY-SA 4.0<br> scanning facility: Fraunhofer Development Center X-ray Technology EZRT/Fraunhofer IIS<br> scanning device: High Energy CT XXL-CT<br> Funding attribution: German Federal Ministry of Education and Research<br> acknowledgement: CryptoMuseum (as main source for informations about the cipher machines)
description: Funding: German Federal Ministry of Education and Research (BMBF), grant programme: eHeritage.
DOI: 10.5281/zenodo.8120922
title: Cipher Machine Siemens Mischer 178 (Inv. 1989-626)

description: This dataset represents the computed tomography image acquisition of a historical cipher machine from the collection of the Deutsches Museum. It is composed of CT reconstructed image stacks in the DICOM (.dcm) format.<br> It can be imported in any free or propietary CT-Viewer that supports the DICOM standard to generated 2D and 3D imaging.<br> If segmentations/ROIs are availabe, they are uploaded in a seperate image stacks and are a subset of the scanned cipher machine. object details:<br> name: Siemens Mischer 178<br> Inv.-No. of the Deutsches Museum: 1989-626 file object details:<br> file format: image/dcm<br> pixel spacing unit: mm<br> X pixel spacing: 0.670<br> Y pixel spacing: 0.670<br> Z pixel spacing: 0.600<br> grid size x: 569<br> grid size y: 492<br> grid size z: 1099<br> color depth: 16Bit ownership & image acquisition:<br> project: 3D-Cipher<br> collection: Deutsches Museum<br> IP holder: Deutsches Museum<br> license: Creative Commons BY-SA 4.0<br> scanning facility: Fraunhofer Development Center X-ray Technology EZRT/Fraunhofer IIS<br> scanning device: High Energy CT XXL-CT<br> Funding attribution: German Federal Ministry of Education and Research<br> acknowledgement: CryptoMuseum (as main source for informations about the cipher machines)
description: Funding: German Federal Ministry of Education and Research (BMBF), grant programme: eHeritage.
DOI: 10.5281/zenodo.8120632
title: Cipher Machine Hagelin H-4605 (Inv. 1987-181)

description: This dataset represents the computed tomography image acquisition of a historical cipher machine from the collection of the Deutsches Museum. It is composed of CT reconstructed image stacks in the DICOM (.dcm) format.<br> It can be imported in any free or propietary CT-Viewer that supports the DICOM standard to generated 2D and 3D imaging.<br> If segmentations/ROIs are availabe, they are uploaded in a seperate image stacks and are a subset of the scanned cipher machine.<br> <br> object details:<br> name: Hagelin H-4605<br> Inv.-No. of the Deutsches Museum: 1987-181 file object details:<br> file format: image/dcm<br> pixel spacing unit: mm<br> X pixel spacing: 0.126<br> Y pixel spacing: 0.126<br> Z pixel spacing: 0.126<br> grid size x: 2500<br> grid size y: 2998<br> grid size z: 1719<br> color depth: 16Bit ownership & image acquisition:<br> project: 3D-Cipher<br> collection: Deutsches Museum<br> IP holder: Deutsches Museum<br> license: Creative Commons BY-SA 4.0<br> scanning facility: Fraunhofer Development Center X-ray Technology EZRT/Fraunhofer IIS<br> scanning device: High Energy CT XXL-CT<br> Funding attribution: German Federal Ministry of Education and Research<br> acknowledgement: CryptoMuseum (as main source for informations about the cipher machines)
description: Funding: German Federal Ministry of Education and Research (BMBF), grant programme: eHeritage.
DOI: 10.5281/zenodo.8120631
title: Cipher Machine Hagelin H-4605 (Inv. 1987-181)

description: This dataset represents the computed tomography image acquisition of a historical cipher machine from the collection of the Deutsches Museum. It is composed of CT reconstructed image stacks in the DICOM (.dcm) format.<br> It can be imported in any free or propietary CT-Viewer that supports the DICOM standard to generated 2D and 3D imaging.<br> If segmentations/ROIs are availabe, they are uploaded in a seperate image stacks and are a subset of the scanned cipher machine.<br> <br> object details:<br> name: Hagelin H-4605<br> Inv.-No. of the Deutsches Museum: 1987-181 file object details:<br> file format: image/dcm<br> pixel spacing unit: mm<br> X pixel spacing: 0.126<br> Y pixel spacing: 0.126<br> Z pixel spacing: 0.126<br> grid size x: 2500<br> grid size y: 2998<br> grid size z: 1719<br> color depth: 16Bit ownership & image acquisition:<br> project: 3D-Cipher<br> collection: Deutsches Museum<br> IP holder: Deutsches Museum<br> license: Creative Commons BY-SA 4.0<br> scanning facility: Fraunhofer Development Center X-ray Technology EZRT/Fraunhofer IIS<br> scanning device: High Energy CT XXL-CT<br> Funding attribution: German Federal Ministry of Education and Research<br> acknowledgement: CryptoMuseum (as main source for informations about the cipher machines)
description: Funding: German Federal Ministry of Education and Research (BMBF), grant programme: eHeritage.
DOI: 10.5281/zenodo.8116429
title: Cipher Machine Hagelin TC-55 (Inv. 1987-179)

description: This dataset represents the computed tomography image acquisition of a historical cipher machine from the collection of the Deutsches Museum. It is composed of CT reconstructed image stacks in the DICOM (.dcm) format.<br> It can be imported in any free or propietary CT-Viewer that supports the DICOM standard to generated 2D and 3D imaging.<br> If segmentations/ROIs are availabe, they are uploaded in a seperate image stacks and are a subset of the scanned cipher machine. object details:<br> name: Hagelin TC-55<br> Inv.-No. of the Deutsches Museum: 1987-179 file object details:<br> file format: image/dcm<br> pixel spacing unit: mm<br> X pixel spacing: 0.668<br> Y pixel spacing: 0.668<br> Z pixel spacing: 0.601<br> grid size x: 824<br> grid size y: 621<br> grid size z: 664<br> color depth: 16Bit ownership & image acquisition:<br> project: 3D-Cipher<br> collection: Deutsches Museum<br> IP holder: Deutsches Museum<br> license: Creative Commons BY-SA 4.0<br> scanning facility: Fraunhofer Development Center X-ray Technology EZRT/Fraunhofer IIS<br> scanning device: High Energy CT XXL-CT<br> Funding attribution: German Federal Ministry of Education and Research<br> acknowledgement: CryptoMuseum (as main source for informations about the cipher machines)
description: Funding: German Federal Ministry of Education and Research (BMBF), grant programme: eHeritage.
DOI: 10.5281/zenodo.8116430
title: Cipher Machine Hagelin TC-55 (Inv. 1987-179)

description: This dataset represents the computed tomography image acquisition of a historical cipher machine from the collection of the Deutsches Museum. It is composed of CT reconstructed image stacks in the DICOM (.dcm) format.<br> It can be imported in any free or propietary CT-Viewer that supports the DICOM standard to generated 2D and 3D imaging.<br> If segmentations/ROIs are availabe, they are uploaded in a seperate image stacks and are a subset of the scanned cipher machine. object details:<br> name: Hagelin TC-55<br> Inv.-No. of the Deutsches Museum: 1987-179 file object details:<br> file format: image/dcm<br> pixel spacing unit: mm<br> X pixel spacing: 0.668<br> Y pixel spacing: 0.668<br> Z pixel spacing: 0.601<br> grid size x: 824<br> grid size y: 621<br> grid size z: 664<br> color depth: 16Bit ownership & image acquisition:<br> project: 3D-Cipher<br> collection: Deutsches Museum<br> IP holder: Deutsches Museum<br> license: Creative Commons BY-SA 4.0<br> scanning facility: Fraunhofer Development Center X-ray Technology EZRT/Fraunhofer IIS<br> scanning device: High Energy CT XXL-CT<br> Funding attribution: German Federal Ministry of Education and Research<br> acknowledgement: CryptoMuseum (as main source for informations about the cipher machines)
description: Funding: German Federal Ministry of Education and Research (BMBF), grant programme: eHeritage.
DOI: 10.5281/zenodo.8120881
title: Cipher Machine Hagelin CD-57 (Inv. 1987-42)

description: This dataset represents the computed tomography image acquisition of a historical cipher machine from the collection of the Deutsches Museum. It is composed of CT reconstructed image stacks in the DICOM (.dcm) format.<br> It can be imported in any free or propietary CT-Viewer that supports the DICOM standard to generated 2D and 3D imaging.<br> If segmentations/ROIs are availabe, they are uploaded in a seperate image stacks and are a subset of the scanned cipher machine. object details:<br> name: Hagelin CD-57<br> Inv.-No. of the Deutsches Museum: 1987-42 file object details:<br> file format: image/dcm<br> pixel spacing unit: mm<br> X pixel spacing: 0.154<br> Y pixel spacing: 0.154<br> Z pixel spacing: 0.154<br> grid size x: 593<br> grid size y: 362<br> grid size z: 974<br> color depth: 16Bit ownership & image acquisition:<br> project: 3D-Cipher<br> collection: Deutsches Museum<br> IP holder: Deutsches Museum<br> license: Creative Commons BY-SA 4.0<br> scanning facility: Fraunhofer Development Center X-ray Technology EZRT/Fraunhofer IIS<br> scanning device: High Energy CT XXL-CT<br> Funding attribution: German Federal Ministry of Education and Research<br> acknowledgement: CryptoMuseum (as main source for informations about the cipher machines)
description: Funding: German Federal Ministry of Education and Research (BMBF), grant programme: eHeritage.
DOI: 10.5281/zenodo.8120882
title: Cipher Machine Hagelin CD-57 (Inv. 1987-42)

description: This dataset represents the computed tomography image acquisition of a historical cipher machine from the collection of the Deutsches Museum. It is composed of CT reconstructed image stacks in the DICOM (.dcm) format.<br> It can be imported in any free or propietary CT-Viewer that supports the DICOM standard to generated 2D and 3D imaging.<br> If segmentations/ROIs are availabe, they are uploaded in a seperate image stacks and are a subset of the scanned cipher machine. object details:<br> name: Hagelin CD-57<br> Inv.-No. of the Deutsches Museum: 1987-42 file object details:<br> file format: image/dcm<br> pixel spacing unit: mm<br> X pixel spacing: 0.154<br> Y pixel spacing: 0.154<br> Z pixel spacing: 0.154<br> grid size x: 593<br> grid size y: 362<br> grid size z: 974<br> color depth: 16Bit ownership & image acquisition:<br> project: 3D-Cipher<br> collection: Deutsches Museum<br> IP holder: Deutsches Museum<br> license: Creative Commons BY-SA 4.0<br> scanning facility: Fraunhofer Development Center X-ray Technology EZRT/Fraunhofer IIS<br> scanning device: High Energy CT XXL-CT<br> Funding attribution: German Federal Ministry of Education and Research<br> acknowledgement: CryptoMuseum (as main source for informations about the cipher machines)
description: Funding: German Federal Ministry of Education and Research (BMBF), grant programme: eHeritage.